{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-296553","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.372654+00:00","generated_at":"2026-06-21T11:07:16.776798+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maravai settles noncompete lawsuit; Martin to become President, then CEO in July 2023","bullets":["Trey Martin to serve as President of Biologics Safety Testing segment from Dec 5, 2022.","Martin expected to become CEO on July 27, 2023, per settlement with Danaher entities.","Settlement limits Martin's responsibilities and bars involvement in Nucleic Acid Production segment until July 26, 2023.","Carl Hull continues as Executive Chairman and interim CEO; lawsuit voluntarily dismissed.","Christine Dolan remains COO of Biologics Safety Testing segment, reporting to Martin."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-296553","json":"https://secwatch.observer/filing/0001193125-22-296553.json","markdown":"https://secwatch.observer/filing/0001193125-22-296553.md","text":"https://secwatch.observer/filing/0001193125-22-296553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/0001193125-22-296553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/d428491d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:07:16.776798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2727832ad6","claim":"William \"Trey\" Martin, III changed role as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..","evidence_excerpt":"its expectation that Martin will assume the role of Chief Executive Officer of the Company effective July 27, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/0001193125-22-296553-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assume the role of"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7b8e7709e1","claim":"William \"Trey\" Martin, III was appointed as President of Biologics Safety Testing Segment at MARAVAI LIFESCIENCES HOLDINGS, INC..","evidence_excerpt":"William “Trey” Martin, III to serve as President of Maravai’s Biologics Safety Testing Segment beginning December 5, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/0001193125-22-296553-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"to serve as"},{"label":"Role","value":"President of Biologics Safety Testing Segment"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}